Clinical trial
A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease
NCT03710707 is registered in ClinicalTrials.gov with Denali Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease
- Lead sponsor
- Denali Therapeutics Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 4, 2018
- Completion date
- December 6, 2019
- Enrollment
- 29 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.